Skip to main
ARDX

Ardelyx (ARDX) Stock Forecast & Price Target

Ardelyx (ARDX) Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 71%
Buy 29%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Ardelyx is a promising biopharmaceutical company that has developed a platform for discovering new biological mechanisms and pathways to develop innovative therapies with few side effects. The recent market volatility for its two FDA-approved products, Ibsrela and Xphozah, created an entry point for its stock, as Ardelyx maintains an excellent chance of success in the treatment space. The company has a strong pipeline and has established key partnerships with specialty pharmacies, increasing the likelihood of successful commercialization.

Bears say

Ardelyx is facing reimbursement headwinds and challenges in fulfilling times for their product Ibsrela due to timing and the departure of their Chief Commercial Officer. Additionally, the company's expansion into the treatment of Chronic Idiopathic Constipation (CIC) may not be enough to offset potential setbacks and low patient satisfaction with current treatment options.

Ardelyx (ARDX) has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 71% of analysts recommend a Strong Buy, 29% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Ardelyx and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Ardelyx (ARDX) Forecast

Analysts have given Ardelyx (ARDX) a Strong Buy based on their latest research and market trends.

According to 7 analysts, Ardelyx (ARDX) has a Strong Buy consensus rating as of Sep 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $13.29, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $13.29, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Ardelyx (ARDX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.